DR30206 / Huadong Medicine, Zhejiang Doer Biologics - LARVOL DELTA

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer (clinicaltrials.gov) - P1/2 | N=186 | Recruiting | Sponsor: Zhejiang Doer Biologics Co., Ltd. | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Apr 2026 ➔ Apr 2027

Trial completion date • Trial primary completion date • Colorectal Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • HER-2

Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=216 | Recruiting | Sponsor: Zhejiang Doer Biologics Co., Ltd. | Trial completion date: Jul 2026 ➔ Sep 2027 | Trial primary completion date: Mar 2026 ➔ Jul 2027

Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastric Cancer • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • PD-L1

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer (clinicaltrials.gov) - P1/2 | N=186 | Recruiting | Sponsor: Zhejiang Doer Biologics Co., Ltd.

New P1/2 trial • Gastrointestinal Cancer • Oncology • Solid Tumor

An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies. (PubMed, Int Immunopharmacol) - "Here, we developed a trifunctional fusion protein, DR30206, composed of Bevacizumab (an antibody against VEGF), and a variable domain of heavy chain of heavy chain antibody (VHH) against PD-L1 and the extracellular domain (ECD) protein of TGF-β receptor II (TGF-β RII), which are fused to the N- and C-terminus of Bevacizumab, respectively. Finally, in vivo experiments showed that the antitumor activity of DR30206 was superior to those of monoclonal antibody of PD-L1 or VEGF, PD-L1 and TGF-β bispecific antibody or the combination inhibition of PD-L1 and VEGF. Our findings suggest there is a great potential for DR30206 to become a therapeutic for the treatment of multiple cancer types, especially lung cancer, colon adenocarcinoma and breast carcinoma."

Journal • Breast Cancer • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Lung Adenocarcinoma • Lung Cancer • Oncology • Solid Tumor • TGFB1

Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=182 | Recruiting | Sponsor: Zhejiang Doer Biologics Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=182 | Not yet recruiting | Sponsor: Zhejiang Doer Biologics Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor

The world's first PD-L1/VEGF/TGF-β third antibody, a subsidiary of Huadong Medicine Holdings, was approved for clinical trials [Google translation] (Stockstar) - "On June 29, 2023, Huadong Medicine announced that the clinical trial application for DR30206 for injection declared by its holding subsidiary Zhejiang Doer Biotechnology Co., Ltd. (hereinafter referred to as 'Dorer Bio') has been approved. It is reported that DR30206 for injection is a Class 1 therapeutic biological product independently developed by Daoer Biotech with global intellectual property rights. According to the announcement, DR30206 is an antibody fusion protein targeting PD-L1, VEGF and TGF-β, and its indication is advanced solid tumors."

New trial • Oncology • Solid Tumor